Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wholesalers Should Take Firm Stance in Price Negotiations: FJPWA
May 13, 2002
- Original Makers to Take Tougher Stance against Patent Infringement
May 13, 2002
- BUSINESS NEWS IN BRIEF
May 13, 2002
- Number of Medical Accidents at Special Function Hospitals Totals over 15,000
May 13, 2002
- Fujisawa: Overseas Sales Exceed \150 Bil.
May 13, 2002
- GL Covering All Clinical Research to Be Drafted
May 13, 2002
- Daiichi Starts Research on Thrombosis Genes with Keio Univ.
May 13, 2002
- Monkasho Drafts GL on Intellectual Property Rights
May 13, 2002
- Sysmex Joins Hands with Keio Univ. for Advanced Medicine Project
May 13, 2002
- MPC Required Additional Report on Fibrinogen Product
May 13, 2002
- Nifedipine Effects Equivalent to those of ACE Inhibitors: Bayer
May 13, 2002
- Secondary Prevention Implementation Rate Needs to Be Increased: JHSF Survey
May 13, 2002
- Toxicogenomic Project Aims at Safety Prediction System
May 13, 2002
- REGULATORY NEWS IN BRIEF
May 13, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 13, 2002
- Kenporen, JMA Share Opinions on Review of Medical Fees
May 13, 2002
- 6 New Switch OTC Drugs Recommended for Approval
May 13, 2002
- Specialist System for Surgeons to Begin from June
May 13, 2002
- OTC NEWS IN BRIEF
May 13, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 13, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…